Your Global Leader in Stem Cell Market Research
Did you know that in bone marrow alone, humans can have between 50,000 and 200,000 stem cells?
The use and understanding of stem cells is one of the most promising medical advancements of our time because they might be able to help treat life-threatening or chronic diseases.
But where are stem cells found? Let’s find out. [Read more…]
Cellular Dynamics International (CDI), a FUJIFILM company, is the largest provider of induced pluripotent stem cell (iPSC) products worldwide. iPSCs are a type of laboratory made stem cell that has significant potential for use within regenerative medicine.
In theory, iPSCs have the potential to treat a wide range of diseases, including diabetes, heart diseases, autoimmune diseases, neural decline and more. iPSCs are also being widely implemented for use in drug development and discovery, as well as toxicology screening and personalized medicine.
In this article:
Since September 2016, Cellular Dynamics International (CDI) has been divided into two business units, a Therapeutics Business Unit and a Life Science business unit. CDI’s Therapeutics business unit is focused on developing induced pluripotent stem cell (iPSC) based therapies for ocular, cardiac, neural and oncology applications. In contrast, CDI’s Life Science business unit is focused on developing the research products side of the business.
In addition to CDI, there are many other companies and organizations that are involved with the development of induced pluripotent stem cell (iPSC) therapies, including but not limited to:
There are also a number of companies specializing in iPSC product development, including:
Cellular Dynamics International is one of the most important market participants in the iPSC sector, because of its dominance in both iPSC therapies and life science tools.
PARK CITY, Utah, September 19, 2024 – RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled “Method for Generating Multiple Cellular Products from Single Pluripotent Cell Source”, a significant advancement in the field of regenerative medicine. This patent, granted on April 2, 2024, provides RxCell with exclusive rights to induced pluripotent stem cell (iPSC)-derived cells for therapy across a broad spectrum of diseases. [Read more…]
MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular Dynamics will present iCell Sensory Neurons and other key products in its market-leading neuroscience portfolio at the Society for Neuroscience annual conference in Chicago from October 5-9, 2024 and the Annual Pain Therapeutics Summit in Boston from October 28-29, 2024. [Read more…]
